IPO Project Experience
IPO Project Experience
IPO project experience across industries, listing markets and valuation scopes.
| No. | Company | Industry | Listing Information | Valuation Scope |
|---|---|---|---|---|
| 1 | Londian Wason | New Energy | NYSE, 2026-08 | Equity valuation |
| 2 | Creality | TMT | Hong Kong, 2026-05 | Share-based payments; property valuation |
| 3 | LDRobot | Industrial | Hong Kong, 2026-05 | Enterprise value; share-based payments |
| 4 | Haizhi Technology | TMT | Hong Kong, 2026-02 | Fair value measurements |
| 5 | Ribo Life Science | Pharmaceuticals | Hong Kong, 2026-01 | Property valuation |
| 6 | Iluvatar CoreX | TMT | Hong Kong, 2026-01 | Long-term equity investments; share-based payments |
| 7 | Zhipu AI | TMT | Hong Kong, 2026-01 | Purchase price allocation; goodwill impairment testing; share-based payments |
| 8 | 51WORLD | TMT | Hong Kong, 2025-12 | Financial assets; preferred shares |
| 9 | Guoxia Technology | TMT | Hong Kong, 2025-12 | Share-based payments |
| 10 | JD Industrials | Industrial | Hong Kong, 2025-12 | Financial assets |
| 11 | Biocytogen | Pharmaceuticals | SSE STAR Market, 2025-12 | Biological assets |
| 12 | Moore Threads | TMT | SSE STAR Market, 2025-12 | Shareholding restructuring; share-based payments; financial assets |
| 13 | Jinyan Kaolin New Materials | Energy | Hong Kong, 2025-12 | Property valuation |
| 14 | SERES | Automotive | Hong Kong, 2025-11 | Expected credit losses; long-term equity investments; employee options |
| 15 | SICC | TMT | Hong Kong, 2025-08 | Property valuation |
| 16 | Yimutian | TMT | Nasdaq, 2025-08 | Convertible bonds; employee options; equity valuation |
| 17 | HEC Pharm | Pharmaceuticals | Hong Kong, 2025-08 | Property valuation |
| 18 | Youlan International | Education | Nasdaq, 2025-07 | Purchase price allocation; goodwill impairment testing; preferred shares |
| 19 | Unisound | TMT | Hong Kong, 2025-06 | Employee options; preferred shares; long-term equity investments |
| 20 | TransThera | Pharmaceuticals | Hong Kong, 2025-06 | Equity incentives; equity valuation; intangible assets |
| 21 | Baize Medical | Healthcare | Hong Kong, 2025-06 | PPA; goodwill impairment testing |
| 22 | Shouhui Group | TMT | Hong Kong, 2025-05 | Preferred shares; employee options |
| 23 | Mirxes | Medical Devices | Hong Kong, 2025-05 | Purchase price allocation; goodwill impairment testing |
| 24 | Green Tea | Food & Beverage | Hong Kong, 2025-05 | Valuation for tax reporting |
| 25 | Auntea Jenny | Consumer Goods | Hong Kong, 2025-05 | Employee options; incremental borrowing rate; long-term equity investments |
| 26 | CHAGEE | Consumer Goods | Nasdaq, 2025-04 | Share-based payments; equity valuation |
| 27 | New Gonow Recreational Vehicles | Automotive | Hong Kong, 2025-01 | Share-based payments |
| 28 | Biostar Pharma | Pharmaceuticals | Hong Kong, 2024-10 | Property valuation |
| 29 | Horizon Robotics | TMT | Hong Kong, 2024-10 | Preferred shares; convertible bonds; warrants; long-term equity investments |
| 30 | Baiwang | TMT | Hong Kong, 2024-06 | Warrants; purchase price allocation; preferred shares |
| 31 | Dida | TMT | Hong Kong, 2024-06 | Preferred shares; employee options; convertible bonds |
| 32 | Easou Technology | TMT | Hong Kong, 2024-06 | Preferred shares; employee options |
| 33 | ZEEKR | Automotive | NYSE, 2024-05 | Preferred shares; restricted stock |
| 34 | Qyuns Therapeutics | Pharmaceuticals | Hong Kong, 2024-03 | Preferred shares; options |
| 35 | Concord Healthcare | Healthcare | Hong Kong, 2024-01 | Impairment testing; expected credit losses; convertible bonds |
| 36 | Lancang Ancient Tea | Consumer Goods | Hong Kong, 2023-12 | Inventory |
| 37 | Shiyue Daotian | Consumer Goods | Hong Kong, 2023-10 | Financial liabilities |
| 38 | ZX Inc. | TMT | Hong Kong, 2023-09 | Purchase price allocation; share-based payments; impairment testing of long-term investments |
| 39 | Tuhu Car | TMT | Hong Kong, 2023-09 | Purchase price allocation; share-based payments; equity valuation |
| 40 | ZJLD Group | Consumer Goods | Hong Kong, 2023-04 | Equity value |
| 41 | Kang Le Wei Shi | Pharmaceuticals | Beijing Stock Exchange, 2023-03 | Share-based payments; value testing |
| 42 | Fenbi | Education | Hong Kong, 2023-01 | Preferred shares; employee options |
| 43 | Super Hi International | Food & Beverage | Hong Kong, 2022-12 | Asset disposals |
| 44 | ECARX | TMT | Nasdaq, 2022-12 | Share-based payments; warrants; equity valuation |
| 45 | Gaush Meditech | Healthcare | Hong Kong, 2022-12 | Purchase price allocation; convertible bonds; preferred shares; guarantee rights |
| 46 | Flowing Cloud | TMT | Hong Kong, 2022-10 | Preferred shares; equity valuation |
| 47 | Biocytogen | Biopharmaceuticals | Hong Kong, 2022-09 | Employee options; biological assets; enterprise value |
| 48 | Longsys | TMT | Shenzhen Stock Exchange, 2022-05 | Equity valuation |
| 49 | Rainmed | Healthcare (Medical Devices) | Hong Kong, 2022-07 | Preferred shares; employee options; enterprise value |
| 50 | SANY Renewable Energy | Wind Power | SSE STAR Market, 2022-06 | Purchase price allocation |
| 51 | Zhihu | TMT | Hong Kong, 2022-04 | Employee options; preferred shares |
| 52 | UJU Holding | TMT | Hong Kong, 2021-11 | Employee options; enterprise valuation |
| 53 | Acotec Scientific | Healthcare (Medical Devices) | Hong Kong, 2021-08 | Equity valuation; purchase price allocation; employee options; preferred shares |
| 54 | Chaoju Eye Care | Healthcare (Ophthalmology) | Hong Kong, 2021-07 | Equity valuation; purchase price allocation; goodwill impairment testing; share-based payments |
| 55 | JD Logistics | TMT | Hong Kong, 2021-05 | Equity valuation; purchase price allocation |
| 56 | Bairong | TMT | Hong Kong, 2021-03 | Equity valuation; preferred equity valuation; employee options |
| 57 | Zhihu | TMT | NYSE, 2021-03 | Preferred equity valuation; employee options |
| 58 | First High-School Education | Education | NYSE, 2021-03 | Purchase price allocation; employee options; leased properties; goodwill impairment testing |
| 59 | Cheerwin Group | Consumer Goods | Hong Kong, 2021-03 | Enterprise valuation for tax purposes |
| 60 | Kuaishou | TMT | Hong Kong, 2021-02-05 | Available-for-sale financial assets |
| 61 | Kuke Music | TMT | NYSE, 2021-01 | Preferred shares; share-based payments |
| 62 | Jacobio Pharmaceuticals | Pharmaceuticals | Hong Kong, 2020-12 | Equity valuation; preferred equity valuation; employee options |
| 63 | Jinhui Holdings | Real Estate | Hong Kong, 2020-10 | Purchase price allocation; share-based payments |
| 64 | First Service Holding | Real Estate | Hong Kong, 2020-10 | Purchase price allocation |
| 65 | Zonbong Landscape | Engineering | Hong Kong, 2021-01 | Purchase price allocation; biological assets; available-for-sale assets |
| 66 | Newlink Technology | TMT | Hong Kong, 2021-01 | Business valuation |
| 67 | G.H.Y Culture & Media | Film & Media | Singapore, 2020-12 | Expected credit loss assessment; purchase price allocation |
| 68 | Farasis Energy | New Energy | SSE STAR Market, 2020-07 | Preferred shares; share-based payments |
| 69 | Immunotech Biopharm | Pharmaceuticals | Hong Kong, 2020-07 | Equity valuation; preferred equity valuation; employee options |
| 70 | Hepalink | Pharmaceuticals | Hong Kong, 2020-07 | Fund financial assets (equity valuation); purchase price allocation; convertible bonds; warrants; share-based payments |
| 71 | BlueCity | TMT | Nasdaq, 2020-07 | Purchase price allocation |
| 72 | Quhuo | TMT | Nasdaq, 2020-07 | Purchase price allocation; employee options; intangible assets |
| 73 | Legend Biotech | Pharmaceuticals | Nasdaq, 2020-06 | Allocation of licensing agreement value |
| 74 | Hygeia Healthcare | Healthcare | Hong Kong, 2020-06 | Preferred shares; purchase price allocation; restricted stock; goodwill impairment testing |
| 75 | WiMi Hologram | TMT | Nasdaq, 2020-04 | Equity valuation |
| 76 | AnPac Bio | Biomedical | Nasdaq, 2020-01 | Share-based payments; purchase price allocation; asset impairment testing; equity valuation |
| 77 | Lizhi FM | TMT | Nasdaq, 2020-01 | Preferred shares; share-based payments; equity valuation |
| 78 | Newborn Town | TMT | Hong Kong, 2020-01 | Purchase price allocation; preferred shares; available-for-sale assets |
| 79 | Pharmaron | Biomedical | Hong Kong, 2019-11 | Property valuation |
| 80 | China Feihe | Consumer Goods | Hong Kong, 2019-11 | Financial review and reconciliation |
| 81 | CMGE | TMT | Hong Kong, 2019-10 | Fund financial assets (equity valuation); convertible bonds; contingent consideration; purchase price allocation; goodwill impairment testing |
| 82 | Xinyuan Property | Property Management | Hong Kong, 2019-10 | Equity valuation; share-based payments; restricted stock; purchase price allocation; goodwill impairment testing |
| 83 | EuroEyes | Healthcare (Ophthalmology) | Hong Kong, 2019-10 | Equity valuation; purchase price allocation; share-based payments |
| 84 | JH Educational | Education | Hong Kong, 2019-06 | Property valuation; purchase price allocation; goodwill impairment testing |
| 85 | China Kepei Education | Education | Hong Kong, 2019-01 | Property valuation; purchase price allocation; goodwill impairment testing; share-based payments |
| 86 | Inke | TMT | Hong Kong, 2018-07 | Purchase price allocation; goodwill impairment testing; financial assets; share-based payments |
| 87 | China New Higher Education | Education | Hong Kong, 2017-04 | Property valuation; purchase price allocation; goodwill impairment testing |
| 88 | Yuhua Education | Education | Hong Kong, 2017-03 | Property valuation; purchase price allocation; convertible bonds |
No matching projects. Please adjust your filters.
Records are compiled from the company profile. Listing information and valuation scopes follow the source materials; separate listings for the same client are shown individually.
